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BACKGROUND AND PURPOSE
Targeting more than one opioid receptor type simultaneously may have analgesic advantages in reducing side-effects. We have
evaluated the mixed μ opioid receptor agonist/ δ opioid receptor antagonist UFP-505 in vitro and in vivo.
EXPERIMENTAL APPROACH
We measured receptor density and function in single μ, δ and μ /δ receptor double expression systems. GTPγ35S binding,
cAMP formation and arrestin recruitment were measured. Antinociceptive activity was measured in vivo using tail withdrawal
and paw pressure tests following acute and chronic treatment. In some experiments, we collected tissues to measure
receptor densities.
KEY RESULTS
UFP-505 bound to μ receptors with full agonist activity and to δ receptors as a low efficacy partial agonist At μ, but not δ receptors,
UFP-505 binding recruited arrestin. Unlike morphine, UFP-505 treatment internalized μ receptors and there was some evidence
for internalization of δ receptors. Similar data were obtained in a μ /δ receptor double expression system. In rats, acute UFP-505 or
morphine, injected intrathecally, was antinociceptive. In tissues harvested from these experiments, μ and δ receptor density was
decreased after UFP-505 but not morphine treatment, in agreement with in vitro data. Both morphine and UFP-505 induced
significant tolerance.
CONCLUSIONS AND IMPLICATIONS
In this study, UFP-505 behaved as a full agonist at μ receptors with variable activity at δ receptors. This bifunctional com-
pound was antinociceptive in rats after intrathecal administration. In this model, dual targeting provided no advantages in
terms of tolerance liability.
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Introduction
Opioids have been the main treatment option for pain for
centuries, but their use is associated with a number of
troublesome side effects, including respiratory depression, con-
stipation, immune suppression, physical dependence and toler-
ance (Dietis et al., 2011; Sehgal et al., 2013). Analgesic tolerance
is a long-term process, which is distinct to the rapid process of
desensitization that arises from chronic administration of
opioids (Dang andChristie, 2012).When analgesic tolerance oc-
curs, the patient requires increasingly higher doses of the drug
in order to achieve adequate analgesia. As these higher doses
result in increased side effects, including tolerance itself, it is
easy to appreciate that tolerance drives an inevitable vicious
clinical circle of increasing doses and increased side effects,
which is the end result of chronic opioid use (Dietis et al.,
2009). Clinically, an increase in opioid analgesia can be achieved
by switching opioid or adding an adjuvant, and the World
Health Organization analgesic ladder describes this from a prac-
tical standpoint. However, a short-term increase in analgesia
does not attenuate the development of tolerance, and therefore,
a reduction in the degree of analgesia achieved is inevitable.
Therefore, reducing the propensity for tolerance in novel opi-
oids is an efficient strategy for providing adequate analgesia
without detrimental dose-escalation.
Opioid receptors are members of a large family compris-
ing the μ, δ, κ and the ‘opioid-like’ nociceptin/orphanin
FQ receptor (NOP; Lambert, 2008; Dietis et al., 2011; Toll
et al., 2018). Almost all clinically available (and pharmaceuti-
cal developed) opioid analgesics target mainly the μ recep-
tors, although there is current evidence for constitutive
interactions among receptor subtypes (dimerization) thatmight
change the way we think about the drug–target relationship of
opioids (Gupta et al., 2006). With relevance to our study, the
most functionally important interaction of opioid receptors
occurs between the μ and δ receptors (Law et al., 2005). Gomes
et al. (2000) provided evidence that μ-δ receptor dimers possess
functional and ligand binding synergy, whereas George et al.
(2000) showed a distinct binding profile of opioid ligands at μ-
δ receptor dimers. More interestingly, however, a number of
earlier studies in rodents have shown that when δ receptors are
blocked by an antagonist (Abdelhamid et al., 1991; Hepburn
et al., 1997) or the gene is knocked out (Zhu et al., 1999) or
knocked down (Kest et al., 1996), or the gene for the endoge-
nous δ receptor agonist enkephalin is knocked out (Nitsche
et al., 2002), then tolerance to morphine is reduced.
From a drug development perspective, it is preferable to
use a single molecule to simultaneously target the μ and δ
receptors, rather than co-administering two separate drugs,
both from a pharmacokinetic point of view and reduced drug
interactions. For this purpose, two chemical types of opioids
can be considered: bifunctional opioids (e.g. opioids that
have two distinct binding properties) and bivalent opioids
(e.g. opioids that possess two distinct pharmacophores in
their structure) (Dietis et al., 2009). Although these two types
of ‘dual’ opioids have been well described in the literature
during the last decade, their differentiation in terms of advan-
tages in chemical design or molecular efficacy is not yet clear.
Our group has used the bifunctional opioid H-Dmt-Tic-
Gly-NH-Bzl (UFP-505) as a prototype μ receptor agonist and
δ receptor antagonist (Balboni et al., 2010; Dietis et al.,
2012) and hypothesized that this opioid ligand will produce
antinociceptive actions in vivo with reduced analgesic toler-
ance liability. Here, we present our data from relevant in vivo
assays on the tolerance, as well as new data on this ligand’s
effects on opioid receptor density and trafficking from assays
in vitro, at recombinant μ and δ receptors and at μ /δ double
expression receptor systems, and ex vivo, using rat tissues.
Methods
Additional information for thematerials used can be found in
the Supporting Information.
Cell culture
CHO cells stably expressing a single type of human opioid
receptor (μ receptors, hMOP and δ receptors, hDOP) and cells
with high expression of human δ receptors (CHOhDOP/high)
were grown as described previously (Dietis et al., 2012). Stock
cultures were supplemented with 200 μg·mL1 geneticin
(G418), for CHOhMOP, CHOhDOP and CHOhDOP/high cells,
and with additional 200 μg·mL1 hygromycin B for the novel
CHOhMOP/hDOP cell line (see below). Cell cultures were kept at
37°C in 5% CO2/humidified air and subcultured as required
using trypsin/EDTA. Cells were used for experimentation as
they approached confluence and were selection agent free.
Novel cell line stably expressing human μ and δ
receptors
A novel CHO cell line stably expressing the human μ and δ
receptors (CHOhMOP/hDOP) was produced by transfecting
geneticin-resistant CHOhMOP cells with human δ receptor
cDNA in a hygromycin B-selectable vector (pcDNA3.
1Hygro(+)/OPRD1; S&T Missouri University, USA) and
selected with 800 μg·mL1 hygromycin B and 500 μg·mL1
geneticin (GIBCO, UK). Initially, the transfection of human
δ receptors in CHOhMOP cells produced a polyclonal mixture
which was further subcloned producing a final number of
30 CHOhMOP/hDOP clones. To narrow the selection for the
appropriate monoclonal cell batch, all clones were screened
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by qRT-PCR and their μ and δ receptor mRNA expression
levels were determined. The top three clones that showed
the highest transfection efficiency were used in radioligand
binding assays to determine receptor protein expression.
One clone was selected for use, and binding data are
described in the Results section. Cell culturing of
CHOhMOP/hDOP cells was as described above with double
selection pressure.
Saturation-binding assay to determine receptor
density
Membrane protein from CHO cells (70–100 μg; prepared as
described in the Supporting Information) was incubated in
0.5 mL volume of 50 mM Tris, 0.5% BSA, with a variety of
peptidase inhibitors (amastatin, bestatin, captopril and
phosphoramidon) at 10 μM and various concentrations of
radioligand [3H]-diprenorphine ([3H]-DPN) for 1 h at
room temperature. Tritiated DAMGO ([3H]-DAMGO) and
tritiated naltrindole ([3H]-NT) was used for labelling μ
and δ receptors, respectively, in saturation binding assays as
appropriate. In some experiments (as noted in Results), full
saturation analysis was performed, and in others, a saturating
radioligand concentration was used. Non-specific binding
(NSB) was defined in the presence of 10 μM naloxone.
Reactions were terminated and bound/free radioactivity were
separated by vacuum filtration through polyethylenimine-
soaked (0.5%) Whatman GF/B filters, using a Brandel
harvester. Bound radioactivity was determined after 8 h
extraction in ScintisafeGel (Wallac, Loughborough, UK)
using liquid scintillation spectroscopy.
Displacement binding assay to determine
ligand selectivity and binding affinity
Membrane protein (70–100 μg) was incubated. as in the satu-
ration assays, but containing ~1 nM [3H]-DPN and varying
concentrations (1 pM to 10 μM) of a range of displacer
ligands. NSB was defined in the presence of 10 μM naloxone.
Assay incubation time, reaction termination and bound
radioactivity were the same as in the saturation assay.
GTPγ35S assay to determine ligand functional
activity
Membrane protein (70–100 μg) was incubated in 0.5 mL
volume of 50 mM Tris, 0.2 mM EGTA, 1 mM MgCl2–6H2O,
100 mM NaCl, pH 7.4 supplemented with 0.1% BSA,
0.15 mM bacitracin, GDP (33 μM) and ~150 pM GTPγ35S
with gentle shaking for 1 h at 30°C. NSB was determined
in the presence of non-radiolabelled 10 μM GTPγS. Reac-
tions were terminated by vacuum filtration through dry
Whatman GF/B filters, using a Brandel harvester. Bound
radioactivity was determined as in the saturation assays.
Endomorphin-1 (EM1), [D-Pen2,D-Pen5]-enkephalin
(DPDPE) or UFP-505 were included where appropriate at
various concentrations and combinations as described in
the Results section.
Inhibition of forskolin-stimulated cAMP
formation
CHO whole-cell suspensions were incubated in 300 μL
Krebs/HEPES buffer (143mMNaCl, 4.7mMKCl, 2.6mMCaCl2,
1.2 mM MgSO4, 1.2 mM KH2PO2, 12 mM glucose and 10 mM
HEPES, pH to 7.4) containing 0.5% BSA, 1 mM IBMX, 1 μM
forskolin and 10 μM of EM1, DPDPE and UFP-505. Reactions
were incubated for 15 min at 37°C, with gentle shaking, termi-
nated by addition of 20 μL 10 M HCl, neutralized by addition
of 20 μL 10 M NaOH and buffered to pH 7.4 by addition of
200 μL 1 M Tris–HCl. Cellular debris was cleared by centrifuga-
tion and the resulting supernatants assayed for cAMP forma-
tion, against cAMP standards, in a competitive binding assay
with [3H] cAMP using a binding protein extracted from bovine
adrenal glands, as described previously (Kitayama et al., 2007).
Bound and free radioactivity were separated by the addition of
250 μL of charcoal mixture (250 mg charcoal, 100 mg BSA per
25 mL solution, 50 mM Tris–HCl and 4 mM EDTA buffer at
pH 7.4). Each tube was allowed to stand for 1 min before
centrifugation at 12000× g in a Sarstedt microfuge at room
temperature. The supernatant (200 μL) was taken and mixed
with 1 mL of Optiphase Hi-Safe scintillation liquid, and radio-
activity was counted using liquid scintillation spectroscopy.
Receptor internalization and receptor
desensitization assays
For the internalization study, cells (grown in large T175 flasks)
were incubated with appropriate concentration of a given
ligand in 20 mL of fresh culture medium for an appropriate
time according to the experiment and as described in the
Results section. Adherent cells were then washed three times
at 4°C with harvest buffer (containing 0.9% saline, 0.02%
EDTA, 10 mM HEPES, pH of 7.4) to remove any receptor-
bound ligand, before harvesting. Membranes were prepared
as previously described (Dietis et al., 2012), washing three
times with buffer prior to three centrifugations at 1600× g
and three centrifugations at 14 000× g, with subsequent
removal of supernatant and resuspension of the pellet, in
order to ensure that all desensitizing ligand is washed off.
Then a saturation binding assay was performed as described
above. For receptor internalization, CHOhMOP cells where
treated with 10 μM of morphine, EM1 or fentanyl
and CHOhDOP with 10 μM DPDPE, as reference compounds
with the maximum concentration used in these experi-
ments, as well as with various concentrations of UFP-505
(1 nM-10 μM) for CHOhMOP or 10 μM for CHOhDOP. For
the desensitization studies, cells were incubated for 1 h
(chosen as the most appropriate for tolerance-related desen-
sitization; based on Williams et al., 2013) with an appropri-
ate ligand at various concentrations (1 pM to 10 μM), and
membranes were prepared as in the internalization study.
A GTPγ35S assay was then performed as described above.
Arrestin assay
The PathHunter® eXpress CHO–K1 pre-validated cell lines
were used (DiscoveRx, Birmingham, UK), expressing human
μ or δ receptors and β-arrestin-2, supplied in an optimized cell
culture medium. The assay measures binding of β-arrestin
with the receptor of interest upon activation by an agonist.
The assay was performed according to the manufacturer’s
instructions. Briefly, cells were thawed and plated in OCC
medium in 96-well luminescence plates and allowed to
recover for 48 h at 37°C. Agonists were added to each well
and incubated for 90 min at 37°C. Detection reagents were
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added and incubated with the cells for 60 min at room
temperature. Chemiluminescence was measured using a
standard 96-well plate luminometer.
Animals
All animal care and experimental procedures complied with
the European Directive (EEC No. 86/609) and the Italian D.
L. 27/01/1992, No.116, and were approved by the University
of Florence or Modena Animal Subjects Review Board. Ethical
guidelines for investigation of experimental pain in
conscious animals were followed. Animal studies are reported
in compliance with the ARRIVE guidelines (Kilkenny et al.,
2010; McGrath and Lilley, 2015).
Healthy male Wistar rats (strain code 003, albino,
200–250 g; Charles Rivers Laboratories, Wilmington, MA,
USA) were used in the tail-flick (TF) antinociception assay
and healthy male Sprague–Dawley rats (280–300 g; Harlan,
Varese, Italy) were used in the paw pressure (PP) and rotarod
assays. Before any surgical or experimental procedures, all an-
imals were housed in groups of two to three under standard
controlled conditions (22 ± 1°C, 12 h light/dark cycle) with
food and water ad libitum for at least 5 days. Animal weight
and visible behavioural changes weremonitored prior, during
and after each experiment. All animals were used at least 1-
week after their arrival in the lab. After surgery and during ex-
periments, all animals were housed singly.
Intrathecal surgery
We initially used an intrathecal (i.t.) catheterization protocol for
animals used in the acute TF test, but it was not possible to retain
the catheters on these animals for long-term exposure (data not
shown). We therefore elected to use an alternative catheteriza-
tion strategy for the rest of the tests used (rotarod and PP). Below,
we describe both protocols used. For the TF test, animals were
anaesthetized by i.p. ketamine and xylazine (115 + 2 mg·kg1;
Farmaceutici Gellini, Aprilia, Italy, and Bayer, Milan, Italy), and
a modification of the Storkson method of i.t. catheterization
was applied (Storkson et al.,1996) at the lumbar regionof the spi-
nal cord (betweenL5andL6; Supporting InformationFigure S1).
After surgery, the correct catheter positioning was assessed by
lidocaine administration (15 μL, 20 mg·mL1, i.t.) followed by
saline (10 μL, i.t.) and subsequent loss of motor control of the
rear limbs within 15 s lasting for 20–30 min. One animal that
did not pass this lidocaine test was excluded from the study.
The animals used in the rotarod and PP assays were
anaesthetized with 2% isoflurane and the i.t. catheter was
surgically implanted according to the method of Yaksh and
Rudy (1976). Rats were shaved on the back of the neck and
placed in the stereotaxic frame with the head securely held
between ear bars. The skin over the nap of the neck was cleaned
with ethyl alcohol and incised for 1 cm. The muscle on either
side of the external occipital crest was detached and retracted
to expose about 3–4 mm2 of the atlanto-occipital membrane.
The membrane was incised by a needle, which led to the escape
of cerebrospinal fluid. The caudal edge of the cut was lifted, and
about 7.0 cm of 28 g polyurethane catheter (0.36 mm outer
diameter; 0.18 mm inner diameter; Alzet, USA) was gently
inserted into the i.t. space in the midline, dorsal to the spinal
cord until the lumbar enlargement. The exit end of the catheter
was connected to 4.0 cm polyurethane (0.84 mm outer diame-
ter; 0.36 mm inner diameter) and was taken out through the
skin, flushed with saline solution, sealed and securely fixed on
the back of the head with a silk suture. The incision site in the
skinwas closedwith polyamide sutures and the animals allowed
to recover for 24 h before the study began. The evaluation of
potential motor dysfunctions induced by the surgery was inves-
tigated using a rotarod test. Any animals displaying motor
disabilities (approximately 10%) were excluded from the PP
behavioural measurements.
Tail-flick test
Animals were submitted to the TF test (15 s cut-off time)
prior to acute i.t. treatment of varying drug concentrations
in order to determine their nociceptive threshold (basal
latency) and after i.t. administration of drugs at times
T = 15, 30, 60, 90 and 120 min to determine treatment
latency. The control group animals were treated with sterile
saline (20 μL) whereas the treatment group animals were
treated with 10 μL (i.t.) of UFP-505 followed by administra-
tion of sterile saline (10 μL, i.t.). Morphine was also used
as a reference compound in a separate animal group, in a
protocol similar to the treatment group.
Rotarod test
The rotarod apparatus (Ugo Basile, Varese, Italy) was
consisted of a base platform and a rotating rod with a diame-
ter of 6 cm and a non-slippery surface. The rod, 36 cm in
length, was placed at a height of 25 cm from the base and
was divided into four equal sections by five disks. Thus, up
to four rats were tested simultaneously on the apparatus, with
a rod-rotating speed of 10 r.p.m. The integrity of motor coor-
dination was assessed on the basis of the number of falls from
the rod during 60 s in acute protocol and 120 s during the re-
peated one. The test was stopped after a maximum of six falls.
Paw pressure test
The mechanical nociceptive threshold in the rat was deter-
mined with the PP test (Ugo Basile, Varese, Italy), according
to the method described by Leighton et al. (1988). A con-
stantly increasing mechanical pressure was applied to the an-
imal’s paw, until occurrence of vocalization or withdrawal
reflex, while the rats were lightly restrained. Vocalization or
withdrawal reflex threshold levels were expressed in grams
of the applied pressure. Animals with basal threshold below
40 g or above 75 g were excluded prior to treatment. Measure-
ments were performed after acute i.t. injection of 0.3–30 nmol
UFP-505 (10 μL). Antinociception was measured at 15, 30, 45
and 60 min after administration with a PP test. Chronic
experiments (8 days) involved in i.t. daily injection of
10 nmol UFP-505 or 3 nmol morphine (in 10 μL), and
antinociception in PP (along with motor coordination using
a rotarod; as described above) was evaluated every day at
30 min after administration. The cut-off threshold for treated
animals in this assay was 150 g. Assessments of PP and motor
coordination were performed independently of each other.
Tissue removal
Animals used in the TF test were killed by decapitation imme-
diately after the end of each experiment, and their spinal cord
tissue and cerebral cortex were isolated while on ice. Tissues
were stored at 80°C and used later for membrane prepara-
tion as described above. Part of the tissues scheduled for later
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PCR analysis were first treated with RNAlater® solution
(AM7020, Applied Biosystems, USA) then stored at 20°C
for 2 days and finally stored at 80°C for 3 days.
Data and statistical analysis
The data and statistical analysis comply with the recommen-
dations on experimental design and analysis in pharmacol-
ogy (Curtis et al., 2015). All data are presented as
mean ± SEM from (n) experiments, as shown in the Figure
and Table legends. Concentration–response curves were
analysed by nonlinear regression using GraphPad Prism
V5.0 software (San Diego, CA, USA). In saturation-binding
assays, the receptor density (Bmax) and radioligand equilib-
rium dissociation constant (pKd) were obtained from
saturation-binding isotherms and semi-log transformations
of specific binding data. In displacement binding assays,
50% displacement of specific binding was corrected for the
competing mass of radiolabel, and the pKi values were
obtained from displacement curves, and values were
determined using nonlinear regression, corrected using the
Cheng-Prusoff equation (Cheng and Prusoff, 1973) (log
{EC50/(1 + [L]/Kd)}), where EC50 is the effective concentration
of the ligand that displaces 50% of the radioligand, [L] the
concentration of the radioligand used, and Kd the dissocia-
tion constant of the radioligand. pEC50 and Emax values in
functional experiments were obtained from the sigmoidal
curve with a variable slope. All statistical analysis was
performed using GraphPad Prism V5.0 software. Some data
were analysed using ‘Origin 9’ software. Student’s t-test and
ANOVA with post hoc testing (Bonferroni) as required were
used, as described in the Table and Figure legends
(significance set at P < 0.05).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked
to corresponding entries in http://www.guidetopharma-
cology.org, the common portal for data from the IUPHAR/
BPS Guide to PHARMACOLOGY (Harding et al., 2018), and
are permanently archived in the Concise Guide to PHARMA-
COLOGY 2017/18 (Alexander et al., 2017).
Results
In vitro characterization of UFP-505
In part of the present study, we have used δ receptor-
expressing cells with receptor density (Figure 1A left
~1.8 pmol mg·protein1), ~1.8 higher than the reported
value in Dietis et al. (2012). In membranes prepared from these
high-δ receptor expressing cells, we found significant but low
partial agonist activity for UFP-505 in a GTPγ35S assay (α 0.28
relative to DPDPE), as shown in Figure 1A right, indicating
a partial agonist activity at δ receptors, at very high (non-
physiological) receptor density. The potency of UFP-505
A
B





hMOP 5.9 ± 2.9 1.9 ± 0.8 (82.6 %)
1.4 ± 1.0 (91.6 %)
[Endomorphin-1]
hDOP 10.0 ± 0.4 8.3 ± 0.4 (18.3 %) 2.9 ± 0.1 (78.6 %)
[DPDPE]









































In vitro pharmacological characterization of UFP-505 in CHO cells. (A, left) Representative curve of a single saturation experiment (from 3
experiments to indicate density only) performed in CHO cells with high density of δ receptors. (A, right) G-protein stimulation by UFP-505 and
DPDPE [(D-Pen2,5)-enkephalin] in these high expressing cells (n = 5 per group). The maximum stimulation (Emax) achieved by UFP-505 binding
was higher than basal levels (unstimulated), but less than that of DPDPE. *P < 0.05; Student’s t-test (B) Effect of UFP-505 and reference agonists
(DPDPE; 10 μM and EM1; 1 μM) on forskolin-stimulated cAMP formation in CHOhMOP and CHOhDOP (lower expression) cells. All data are
presented as mean ± SEM fold increase of basal stimulation (n = 5–6). Percentage inhibition of cAMP is shown in parenthesis. Both DPDPE and
EM1 produced a significant inhibition compared to forskolin (P < 0.05, one-way ANOVA with Bonferroni correction).
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(pEC50; 8.54 ± 0.28) was significantly higher than that of
DPDPE (7.68 ± 0.20) in membranes from these cells.
Downstream from G-protein activation, the cAMP forma-
tion stimulated by forskolin, in CHOhMOP cells was inhibited
by both 1 μMEM1 and 10 μMUFP-505, as shown in Figure 1B.
There was no significant difference between the inhibition of
cAMP formation caused by EM1 and UFP-505, indicating that
UFP-505 behaves as a full agonist in this downstream-
amplified assay. In CHOhDOP cells, 10 μΜ DPDPE inhibited
forskolin-stimulated cAMP formation as expected for a full
agonist at δ receptors (Figure 1B). However, the addition of
10μΜ UFP-505 resulted in a small, but significant, inhibition
of forskolin-stimulated cAMP (α 0.23 relative to DPDPE),
again suggesting that UFP-505 behaves as a low-efficacy,
partial agonist at δ receptors in this highly amplified assay.
This is an important point in discussing the behaviour of
the ligand in vivo at target ‘sites’ with higher expression.
In vitro receptor internalization
Next, we examined the effects of UFP-505 on opioid
receptor turnover. Pretreatment of CHOhMOP cells with
10 μΜ UFP-505 induced a significant loss of surface μ recep-
tors (62%) compared to the non-treated cells (Figure 2A). In
the same assay, pretreatment with 10 μM EM1 or fentanyl
also induced significant μ receptor internalization (~50%
and ~25%, respectively), whereas morphine was ineffective.
To determine whether time of ligand pretreatment had an
effect on the reduction of MOP receptor density, binding
assays with saturating radioligand concentrations were per-
formed after pretreatment of CHOhMOP cells with 10 μΜ
UFP-505 for 1 and 24 h. Pretreatment with UFP-505 (control
Bmax 457 ± 86) for 24 h induced internalization of μ recep-
tors (Bmax 166 ± 15), comparable to the effects of pretreat-
ment for 1 h (Bmax 108 ± 23). These two Bmax values were
not different ( one-way ANOVA with Bonferroni correction).
The decrease in μ receptor density induced by UFP-505
was concentration-dependent, as shown in Figure 2B.
UFP-505 induced a significant internalization of μ receptors
at 10 and 1 μΜ compared to the control (untreated), with a
pEC50 of 6.62. This is similar with the pEC50 produced
from GTPγ35S binding (6.37) but lower than the pKi of
UFP-505 binding (7.79) as shown in previously published
data (Dietis et al., 2012).
Interestingly, in CHOhDOP cells (Figure 2C; Bmax~1000-
fmol·mg1 protein) where UFP-505 behaves as a low-efficacy
partial agonist, 10 μMof UFP-505 induced extensive internal-
ization of δ receptors (~86%), as did the δ receptor full agonist
DPDPE at 10 μM (~80%). The unexpectedly extensive δ
receptor internalization by UFP-505, based on its weak intrin-
sic activity, raised an initial concern that the reduction seen
in this assay could be an artefact, possibly due to an
incomplete wash-off of the desensitizing challenge. In order
to exclude this possibility, full [3H]-DPN saturation curves
were produced from CHOhMOP and CHOhDOP cells pretreated
with 10 μΜUFP-505 after wash off and the pKdwas calculated
(Figure 3). Representative saturation curves are shown here,
from a series of five independent experiments performed
after pretreatment with 10 μΜ fentanyl in CHOhMOP cells
(Figure 3B) and 10 μΜ UFP-505 (Figure 3C). The pKd of the
curves produced were not different from the control
(Figure 3G), confirming that the reduced radioligand binding
Figure 2
Opioid receptor internalization upon ligand binding. (A) μ receptor
density (Bmax; fmol [
3H]-DPN·mg1 protein) in CHOhMOP cells
pretreated for 1 h with various opioid ligands at 10 μM as
determined from binding assays with saturating radioligand concen-
trations. The Bmax values after fentanyl (Fent), EM1 or UFP-505 were
lower than control. *P < 0.05, significantly different from control;
one-way ANOVA with Bonferroni test. (B) Internalization of μ
receptors by UFP-505 is concentration-dependent. The pEC50 of
internalization by UFP-505 was 6.62 ± 0.17. Internalization by
10 μM EM1 or 10 μM morphine is also shown. Data are normalized
to a control (untreated) Bmax (set to 100%). *P < 0.05, significantly
different from control; one-way ANOVA with Bonferroni test.
≠P < 0.05, significantly different from 10 μM morphine. (C) Bmax of
CHOhDOP cells pretreated with 10 μΜ UFP-505 or 10 μΜ DPDPE for
1 h. Both treatments were equally effective. *P < 0.05, significantly
different from control; one-way ANOVA with Bonferroni test. All data
are means ± SEM from n = 5–7.
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shown in the internalization assays and interpreted as a re-
duction in the Bmax is attributed solely to the internalization
of the receptors and not to the presence of residual UFP-505
in the assay. Similarly, representative saturation curves from
CHOhDOP cells (from n = 5) after pretreatment with 10 μΜ
DPDPE (Figure 3E) and 10 μΜ UFP-505 (Figure 3F) are also
shown here, and the resulting pKd of the curves from all
pretreatment groups did not differ from the control.
Arrestin recruitment
As recruitment of arrestin is a critical part of the internali-
zation process, we used the PathHunter® to compare
arrestin recruitment with internalization. In CHOhMOP
cells, UFP-505 induced a concentration-dependent recruit-
ment of β-arrestin to the μ receptor with a pEC50 of 6.91
(Figure 4A), which was not significantly different to the
pEC50 of morphine (6.75). However, at 10 μM, morphine
showed significantly lower Emax than UFP-505, EM1 and
fentanyl, whereas EM1 and fentanyl showed significantly
higher Emax than UFP-505. For the δ receptors, although
DPDPE produced a concentration-dependent recruitment
of β-arrestin upon receptor activation, UFP-505 did not
(Figure 4B). We do not know the receptor density of the
cells used in this assay as they were provided ready-to-go
by the assay manufacturer.
In vitro characterization of the
double-expression system
All of our in vitrowork so far had been with a single expression
system, so in order to mimic the in vivo situation in a simple
system, we produced CHO cells with double expression of μ
and δ receptors. Our selected monoclonal CHOhMOP/hDOP
batch had a Bmax of 672 ± 34 and 159 ± 32 fmol·mg
1
(mean ± SEM) for the μ and δ receptors respectively, using
tritiated naltrindole ([3H]-Nt) and DAMGO ([3H]-DAMGO)
as δ receptor-selective and μ receptor-selective radioligands
Figure 3
Full saturation curves and loss of cell surface receptors after treatment. Internalization of opioid receptors is presented as a reduction in the Bmax
(fmol [3H]-DPN·mg1 protein) in full saturation binding curves of CHOhMOP cells (A–C) and CHOhDOP cells (D–F) pretreated with 10 μM fentanyl,
10 μMDPDPE or 10 μMUFP-505. The lack of effect on the radioligand Kd confirms that the reduced Bmax reflects genuine receptor internalization.
Representative hyperbola are shown for μ or δ receptors from n = 5 experiments. Collective Bmax and pKd values are presented as mean ± SEM in
(G). Bmax values of treated cells were lower than their respective, untreated, controls. *P< 0.05, one-way ANOVA with Bonferroni test. The Bmax of
the UFP-505 treated cells was lower than that of the fentanyl-treated cells. #P< 0.05, one-way ANOVA with Bonferroni test. The same analysis has
shown no significant differences in the pKd between all groups.
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in saturation binding assays. This gave a μ:δ receptor ratio of
4:1. In addition, full saturation curves with the non-selective
ligand [3H]-DPN confirmed the overall expression levels of
both types of opioid receptors to be 851 ± 45 fmol·mg1 as
shown in Figure 5A; the numerical sum of individual μ
receptors (672) and δ receptors (159), was 831 fmol·mg1,
similar to that determined by [3H]-DPN.
Displacement binding assays showed an ‘overall’ DPN
pKd of 9.51 ± 0.19 for the double-expression CHOhMOP/hDOP
cells, similar to the pKd produced for CHOhMOP and CHOhDOP
cells (Dietis et al., 2012). The binding of [3H]-DPN in
CHOhMOP/hDOP membranes was displaced in a
concentration-dependent manner by UFP-505 and
three reference ligands; EM1, naltrindole and morphine
(Figure 5B). The ‘overall’ binding affinity (pKi) of UFP-505 in
CHOhMOP/hDOP membranes was 7.70 ± 0.16 (n = 5), whereas
the binding affinities for the respective reference ligands were
to be 7.53 ± 0.10 (EM1), 7.87 ± 0.07 (naltrindole) and
7.75 ± 0.11 (morphine) respectively.
The capacity of UFP-505 to induce receptor internaliza-
tion in the mixed μ and δ receptor population was then
studied. UFP-505 induced ~62% opioid receptor internaliza-
tion (μ and δ ), significantly higher than morphine which
did not induce significant internalization compared to
control (Figure 5C). Pretreatment of DPDPE and EM1
produced ~27 and ~43% internalization respectively.
In the GTPγ35S assay, pretreatment of CHOhMOP/hDOP cells
with EM1 or UFP-505 produced a significant reduction in the
efficacy (Emax) of both ligands, without change in potency
(pEC50) (Figure 6). The next step from a simple double expres-
sion system was to examine behaviour in vivo in standard
antinociceptive assays acutely and, after chronic treatment,
to assess tolerance.
In vivo characterization of UFP-505
TF test. UFP-505 produced a time- and dose-dependent
antinociceptive response (Figure 7). Treatment with 10 and
50 but not 1 and 3 nmol UFP-505 produced a significant
response. Furthermore, animals treated with 50 nmol UFP-
505 reached and retained the cut-off time from the first
sampling point (15 min) throughout the study to 120 min
(Figure 7A). Morphine, injected i.t., in a dose of 10 nmol
produced a similar antinociceptive profile to UFP-505
(10 nmol), which was not significantly different from 15
min until 90 min after injection. However, morphine
antinociception was significantly reduced at 120 min after
injection. An analysis of UFP-505 dose–response curves for
latency at 120 min after administration and AUC (s·min)
from Figure 7A are shown in Figure 7B. The pED50 values
calculated for each curve were found to be very similar
(8.20 ± 0.05 and 8.19 ± 0.18 respectively) and corresponded
to ED50 values 6.27 and 6.38 nmol.
Paw pressure test. Acute administration of UFP-505 produced
an antinociceptive response that peaked at 15–30 min.





Morphine 6.75 ± 0.07 7.51 ± 0.27
UFP-505 6.91 ± 0.05 9.86 ± 0.33 *
Fentanyl 13.40 ± 0.59 * #
EM1 14.62 ± 0.25 * #
CHOhDOP
(Panel B)
DPDPE 7.93 ± 0.02 6.55 ± 0.16 *
UFP-505 - 0.05 ± 0.01   










































Concentration–response curves for β-arrestin recruitment in CHOhMOP and CHOhDOP cells for various agents. (A) Morphine, fentanyl, EM1 and
UFP-505 in CHOhMOP. (B) DPDPE and UFP-505 in CHOhDOP. Response is presented as relative luminescence units (RLU). Data are mean ± SEM
of n = 5 experiments, performed in duplicate. In the CHOhMOP cells, no significant difference was found between the EC50 values produced from
the morphine and UFP-505 curves. Comparing the 10 μM values among the different agents, the EM1, fentanyl and UFP-505 responses were all
higher than that of morphine; *P< 0.05, whereas the EM1 and fentanyl responses were significantly higher than that of UFP-505; #P< 0.05. There
was no difference between the EM1 and fentanyl responses. All analyses by one-way ANOVA with Bonferroni test. In the CHOhDOP cells, the Emax
values of DPDPE were significantly higher than that of UFP-505 (B; P < 0.05, Student’s t-test).
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to the 30 and 10 nmol doses at 15 and 30 min (Figure 8A).
Based on the mechanical threshold at 15 min, a crude ED50
of ~9 nmol can be estimated, similar to that obtained in
the TF assay. In Figure 8B, the effects of daily administration
of 3 nmol morphine and 10 nmol UFP-505 are shown;
based on previous data (Micheli et al., 2015), this dose of
morphine is equi-effective to 10 nmol UFP-505 in an
acute setting. By days 6–7, animals were tolerant to both
morphine and UFP-505. There were no differences in
the time course for induction of tolerance between the
two ligands.
Rotarod test. In both acute tests using the animals from the
PP animal group, there were no significant effects on
performance at doses up to and including 10 nmol. At
30 nmol UFP-505, there was marked impairment of
locomotor activity of the posterior paws; at the 15 min time
point, the cut-off of six falls was reached (Table 1).
Ex vivo study of neuronal tissue from treated
animals in the TF study
We had the opportunity to collect and analyse the neuro-
nal tissue from the treated rats in order to assess the
receptor turnover in vivo and to compare the produced data
with our in vitro data. Membrane from lysates of rat neuro-
nal tissue (cortex and spinal cord) of acutely treated ani-




CHOhMOP/hDOP pretreatment 1h Bmax Internalizaton
Control (CNT) 851+46 -
10µM  Morphine (M) 812+59 4.48 %
10µM  DPDPE 627+54 26.62 %
10µM  EM1 482+60 43.33 %
10µM  UFP-505 323+37 61.92 %































































































In vitro characterization of a CHOhMOP/hDOP double-expression system. (A) Representative saturation binding curves (hyperbola; left and
sigmoidal; right) performed on CHOhMOP/hDOP cell membranes with increasing concentrations of [
3H]-DPN. NSB was measured in the presence
of 10 μMnaloxone. Single representative curves are presented here from a total of 3 experiments to indicate density only. The radioligand binding
affinity as pKd was 9.51 (Kd 30.9 nM). (B) Displacement of [
3H]-DPN by UFP-505 and reference ligands (naltrindole, morphine and EM1) at
CHOhMOP/hDOP cell membranes. Data are presented as mean ± SEM (n = 5). Receptor binding affinities (pKi) of ligands were calculated using
the Cheng-Prusoff equation; 7.70 ± 0.16 (UFP-505), 7.75 ± 0.11 (morphine), 7.53 ± 0.10 (EM1) and 7.87 ± 0.07 (naltrindole). (C) Receptor
density (Bmax, fmol [
3H]-DPN·mg1 protein) and percentage internalization of receptors in CHOhMOP/hDOP cells pretreated for 1 h with various
ligands, using a saturating concentration of [3H]-DPN. Data are presented as mean ± SEM values (n = 3). Receptor internalization is presented
as a percentage of control.
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EM-1 (Panel A) UFP-505 (Panel B)
pEC50 Emax pEC50 Emax
Control 6.55 ± 0.13 4.02 ± 0.23 7.10 ± 0.07 3.90 ± 0.46
10µM EM-1 6.49 ± 0.14 2.56 ± 0.13 * 6.90 ± 0.17 2.60 ± 0.23 *
10µM UFP-505 6.63 ± 0.17 2.55 ± 0.19 * 6.93 ± 0.15 2.65 ± 0.09 *












































Receptor desensitization in CHOhMOP/hDOP cells. Ligand-mediated GTPγ
35S binding measured in membranes prepared from CHOhMOP/hDOP cells
after pretreatment of CHOhMOP/hDOP cells with 10 μM EM-1 or 10 μΜ UFP-505 (control; no pretreatment) for 1 h and following a challenge with a
range of concentrations of (A) EM-1 or (B) UFP-505. Data are expressed as mean ± SEM (n = 5). There were no significant differences in the pEC50
of either EM-1 or UFP-505 comparing the pretreatment values with the respective control. Pretreatment Emax values for both EM-1 and UFP-505
were lower than control; *P < 0.05; one-way ANOVA with Bonferroni test.
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UFP- 505 10 nmol
UFP-505 3 nmol
UFP- 505 1 nmol
Morphine 10 nmol


















Latency at 120 min









Acute i.t. administration of UFP-505 in the tail flick (TF) nociceptive test. (A) Antinociceptive profile of acute i.t. administration of saline, UFP-505
(1 nmol n = 4; 3 nmol, n = 7; 10 nmol, n = 7; 50 nmol, n = 4) and morphine 10 nmol (n = 7) in rats using a TF assay (15 s cut-off time).
Measurements were taken from 15 to 120 min after a single drug administration. All groups had originally n = 8, but due to a technical failure
in catheter stabilization, only the animals described here successfully completed the experiments. The antinociception recorded at 120 min after
administration for UFP-505 (10 nmol; n = 7) was greater than that of morphine (10 nmol). *P < 0.05, significantly different from saline; #P,0.05,
significantly different from morphine; Student’s t-test. (B) Dose–response curves for UFP-505 produced from the curves in (A), for latency after
120 min of drug administration (expressing antinociception after 2 h) and the corresponding AUC (in s·min, expressing total antinociception).
The antinociceptive potency of UFP-505, as deduced from the 120 min latency curve had pEC50 8.20 ± 0.05 (EC50 6.27 nmol), whereas the
potency from the AUC curve had pEC50 8.19 ± 0.18 (EC50 6.38 nmol).
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labelling the μ and δ receptors with [3H]-DAMGO or [3H]-
Nt, in a series of independent binding assays with saturat-
ing concentrations of radioligand. Processing of these
membranes was based on the same procedures as used for
the membranes from cell lysates. Receptor density values
(Bmax) were calculated, and density changes were expressed
in % difference from saline-treated animals, as shown in
Table 2. Administration of morphine did not induce any
changes in receptor density in the frontal cortex for both
μ and δ receptors. In contrast, treatment with UFP-505 in-
duced a loss of cell surface μ and δ receptors in this tissue,
compared to morphine-treated and untreated membranes.
Additionally, for the spinal cord samples, the effect of
UFP-505 and morphine on cell surface receptor numbers
was similar (internalization of μ receptors : 44.7%, of δ re-
ceptors: 43.1%). A reduction in density of both receptors
was observed in the UFP-505-treated samples compared to
the expression of the respective receptors in the morphine
and untreated samples (Table 1). The ineffectiveness of
morphine to internalize the μ receptors agrees with other
studies (Whistler and von Zastrow, 1998; Zhang et al.,
1998; Bohn et al., 2004) and with the rest of internaliza-
tion data presented later here.
Additionally, the cortex and spinal cord tissue from
treated and non-treated animals were pooled in two discrete
groups and processed as two batches to determine opioid
receptor mRNA expression by RT-qPCR (expressed as ΔCt –
cycle threshold difference values compared to GAPDH;
Table 1
Effect on motor coordination evoked by acute spinal administration of UFP-505
Motor coordination (number of falls)
Compound (nmol/i.t.) Pretest
After treatment (min)
15’ 30’ 45’ 60’
UFP-505 0.3 0 0 0 0 0
UFP-505 1 0 0 0 0 0
UFP-505 3 0 0 0 0 0
UFP-505 10 1.0 ± 0.5 1.0 ± 0.5 0 0 0
UFP-505 30 0 6 ± 0 nd nd nd
The compound was dissolved in saline solution, and a final volume of 10 μL was administered at the lumbar level of the spinal cord by i.t. catheter. Motor
coordination was evaluated by rotarod test measuring the number of falls in 60 s. The 30 nmol UFP-505 dose impaired locomotor activity of the
posterior paws. All data are mean ± SEM, n = 8.
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Intrathecal (i.t.) administration of UFP-505 in PP test. (A) Antinociceptive effect of acute i.t. administration of UFP-505 in PP test. The compound
was dissolved in saline solution, and a final volume of 10 μL was administered at the lumbar level of the spinal cord by i.t. catheter. Antinociception
was evaluated by PP test. UFP-505 (30 nmol) impaired the locomotor activity of the posterior paws (see Table 1, *P< 0.05, compared with pretest
values). (B) Antinociceptive effect of repeated i.t. administration of UFP-505 and morphine in a PP test. The compounds were dissolved in saline
solution, and a final volume of 10 μL was administered at the lumbar level of the spinal cord by i.t. catheter. The treatment was repeated daily, and
antinociception was evaluated 30 min after administration by PP test. All data are mean ± SEM; n = 8. *P < 0.05, significantly different from cor-
responding pretest values; one-way ANOVA with Bonferroni test.
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shown in Supporting Information Table S1). In acutely
morphine-treated animals, variable changes in opioid recep-
tor mRNA levels were observed for all opioid receptors across
all tissues examined. One interesting change that stood out is
that acute i.t. morphine and UFP-505-treated animals showed
up-regulation of the mRNA for the μ receptors in the spinal
cord, but only morphine-treated animals showed simulta-
neous up-regulation of the δ receptors. The data with
morphine align with findings from other studies showing
that exposure to morphine increased the surface expression
of δ receptors in cultured cortical neurons and in neurons
in the dorsal horn of the spinal cord in vivo (Cahill et al.,
2001; Morinville et al., 2003), although these findings were
based on a 48 h exposure to morphine. Furthermore, in the
frontal cortex, only the κ receptor mRNA levels were
shown to up-regulate in morphine-treated animals. In the
rest of the cortex, only the mRNA levels for the δ receptors
were significantly down-regulated in both treatment
groups. Finally, in the same tissues, levels of the mRNA
for the NOP receptor were down-regulated in both treat-
ment groups.
Discussion
Bifunctional opioids have long been studied in opioid
pharmacology, either for exploring the relationship between
different receptor types or aiming to produce opioid ligands
with reduced adverse effects (Dietis et al., 2009; Schiller,
2010). In this study, we show that UFP-505 behaves as a
full agonist at the μ receptor and displays a variable
expression-dependent efficacy at the δ receptor. This bifunc-
tional compound produces antinociception in rats after i.t.
administration.
Partial agonism depends on expression levels
At intermediate levels of expression of δ receptors and in an
unamplified system, UFP-505 behaves as a competitive δ
receptor antagonist (Dietis et al., 2012), and at very high
expression levels in an amplified system, UFP-505 can
display a partial agonist activity. This behaviour agrees with
our previous observations that partial agonist behaviour is
largely depended on receptor expression levels (McDonald
et al., 2003). Indeed, in CHOhDOP cells, we were able to
unmask low efficacy in a GTPγ35S assay (0.28 relative to
DPDPE; unamplified, with δ receptor levels at ~2 pmol·mg1
protein) and in cAMP assay (amplified, with δ receptor levels
at ~1 pmol·mg1 protein). No activity was shown by UFP-505
in the commercial arrestin assay (unamplified, with δ
receptor expression levels unknown) whereas full agonist
activity was shown for the loss of cell surface receptors
(amplified, with δ receptor levels at ~1 pmol·mg1 protein).
Reduced radioligand binding translates to true
loss of cell surface receptors
The accuracy of receptor expression determined by radio-
ligand labelling is sensitive to ‘sticky’ ligands that remain
bound to receptors, as they may reduce radioligand binding
that can be misinterpreted as reduced receptor density. In
our standard experimental protocol, we use extensive wash-
ing when using natural peptide ligands and radiolabelling
(Hashimoto et al., 2002). However, we also constructed a full
saturation curve to [3H]DPN in both μ and δ receptor cell
lines, in order to provide evidence of effective wash-off, with
the resulting Kd of the radioligand being unaffected, indicat-
ing that there was no residual desensitizing challenge present
at the receptor. We therefore conclude that the reduction in
radioligand binding represents a true loss of cell surface
receptors. In addition, we show loss of cell surface receptors
in well-washed membranes from tissues extracted from
whole animals.
Arrestin recruitment and receptor
internalization
Control of post-receptor signalling lies in a coordinated inter-
play between receptor activation and loss of cell surface
receptors by endocytosis (internalization). The recruitment
of β-arrestin-2 plays a central role to the internalization of
opioid receptors and other GPCRs (Zuo, 2005). Early studies
showed that morphine fails to internalize the membrane μ
receptors (Keith et al., 1996), and stimulation of μ receptor
Table 2
In vitro analysis of neuronal tissue taken from i.t.-treated rats




Frontal cortex Saline 73.85 ± 5.50 – 91.68 ± 8.71 –
Morphine 71.64 ± 3.51 3% 96.77 ± 3.09 5.5%
UFP-505 46.91 ± 1.66 36.5% 40.24 ± 1.31 56.1%
Spinal cord Saline 23.08 ± 1.94 – 33.12 ± 3.21 –
Morphine 21.44 ± 0.99 7.1% 32.54 ± 3.85 1.8%
UFP-505 12.76 ± 2.40 44.7% 18.86 ± 2.08 43.1%
aInternalization.
Receptor density (Bmax; fmol radioligand/mg protein) of MOP and DOP receptors as produced from binding experiments with saturating concentration
of radioligand in extensively washed membranes prepared from the frontal cortex and spinal cord tissue, taken from rats treated acutely with either
10 nmol UFP-505 or 10 nmol morphine. Saturation assays were performed using [3H]-DAMGO (≈6.7 nM) and [3H]-NT (≈3.3 nM) respectively. Only the
UFP-505-treated animals showed a reduction in both MOP and DOP Bmax, in both tissues. Data are expressed as means ± SEM for n = 3–4.
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endocytosis by enhanced β-arrestin-2 can counteract the
development of morphine tolerance (Koch et al., 2005).
Nevertheless, the involvement of β-arrestin-2 in morphine
tolerance is more complicated than a straightforward linear
effect, the reduction of cellular levels of β-arrestin-2 may also
attenuate morphine tolerance (Yang et al., 2011; Wang et al.,
2016). In our assay, activation of μ receptors caused the
recruitment of β-arrestin-2 with a rank order of Emax
EM1 > fentanyl > UFP-505 > morphine. UFP-505 was able
to recruit β-arrestin-2 significantly more than morphine.
Despite UFP-505 being a low-efficacy partial agonist at δ
receptors and able to induce internalization, the ligand did
not show any significant recruitment of β-arrestin-2. We do
not know the level of δ receptor expression in this commer-
cial assay, so it is possible that the lack of a partial agonism
response by UFP-505 in the δ receptor-expressing cells of this
assay could be due to the low receptor expression in this
system, unmasked only at higher levels. On the other hand,
there are mechanisms of receptor internalization that are
independent of β-arrestin-2 (Van Koppen and Jakobs, 2004;
Bradbury et al., 2009), and whether these mechanisms are
part of UFP-505 activity is unknown. In addition, the ability
of a ligand to resensitize μ receptors and to promote
recycling is also an important factor for its tolerance profile
(Dang and Christie, 2012), an aspect for UFP-505 that
needs to be clarified. In essence, UFP-505 was shown to
be a ligand unlike morphine in its ability to induce inter-
nalization of μ receptors and therefore seemed to have
the potential to produce reduced analgesic tolerance com-
pared to morphine.
In vitro studies with a double expression system
We aimed to simulate the in vivo situation, where μ and δ
receptors are co-expressed, by producing a stable recombi-
nant CHOhMOP/DOP double expression system. In this system,
morphine failed to internalize both receptors and UFP-505
wasmore effective than EM1 in internalizing μ receptors, data
that are consistent with the single μ receptor expression
system. There was a reduced ability of DPDPE to internalize
δ receptors, and while it is tempting to suggest that this may
potentially result from the dimer, it could be simply a result
of the relatively lower density of δ receptors compared with
μ receptors, in this cell line.
The μ and δ receptors have been shown to co-localize
in vivo (Wang et al., 2005), and their constitutive dimerization
plays a functional role in disease and ligand pharmacology
(Stockton and Devi, 2012; Yekkirala et al., 2012). Double-
expression recombinant systems have been previously used
and showed that the potency of opioids may differentiate
compared to single-opioid receptor expression cell lines
(Yekkirala et al., 2010; Yekkirala et al., 2012). Moreover, the
response of these opioids in the μ / δ co-expression system
has been shown to be reversed with naltrindole, suggesting
a functional interaction between the two receptors. This is
in agreement with Waldhoer et al. (2005) who showed that
heterodimer activation (by 6-guanidinonaltrindole) was
tissue-specific and only occurred at the level of the spinal
cord. Collectively, these data suggest that δ receptor blockade
can reduce the efficacy of morphine when μ receptors are co-
expressed, which agrees with the premise of our study that, as
δ receptor antagonism reduces morphine tolerance, it may
explain why UFP-505 has reduced tolerance liability. In the
longer term, if δ receptor antagonism reduces μ receptor
signalling, then it is possible that this could have a
‘protective effect’ on μ receptors, reducing their ability to
desensitize. More importantly, there is evidence to suggest
that receptor dimer numbers do change in chronic pain
(Costantino et al., 2012), supporting the claims of a vital
physiological role of these receptor dimers in disease.
Certainly, UFP-505 is able to produce internalization and
does not behave like morphine in this respect. In our
double-expression system, the potency of UFP-505 is greater
by fivefold than in the single μ receptor expression system,
suggesting that our bifunctional ligand is interacting with
a functional μ-δ receptor heterodimer. Clearly, further exper-
imentation with tagged opioid receptors and UFP-505 are
required.
In vivo experiments
Acute i.t. injection of UFP-505 produced a robust antino-
ciceptive response in the TF assay with potency (ED50) of
~7 nmol and 10 nmol of UFP-505 was as antinociceptive
as 10 nmol of morphine. More importantly, our data show
that UFP-505 produced prolonged antinociception that
persisted more than 120 min after acute administration,
compared with the time course of morphine antinoci-
ception. Similar data were obtained in the PP test (using a
different catheterization strategy) with ED50 for UFP-505
of ~9 nmol. These data confirm for the first time the
presumption of a strong antinociceptive dose-dependent
effect of UFP-505 as a μ receptor ligand with agonist activity.
Morphine tolerance has been consistently observed in rats
after 3 days with i.t. treatment (Granados-Soto et al., 2000;
Paul et al., 2017) or 5 days with s.c (Goodchild et al., 2009)
or i.p treatment (Chen et al., 2008). We confirmed these
findings for morphine with our long-term testing using
the PP test. Bifunctional ligands with a μ receptor agonist
and δ receptor antagonist profile have been shown to have
reduced tolerance profile (Mosberg et al., 2014), and there-
fore, we expected that UFP-505 would show a similar pro-
file in our long-term tests of paw withdrawal, given its
pharmacological profile in vitro and its analgesic efficacy
in vivo. However, to our surprise, UFP-505 produced a toler-
ance profile that was not significantly different from that
of morphine in our model.
Although we have no data that will offer a mechanistic
explanation of UFP-505’s tolerance profile, there are two
factors that could explain this unexpected result. The first is
the model in which antinociception is assessed. Different
pain models, such as TF, hot-plate, PP, warm water tail-
withdrawal, capsaicin administration and acetic acid
writhing) utilize different types of nociceptive stimuli
(electrical, thermal, mechanical and chemical) that require
the involvement of a mixed variety of neuronal processes
(Le Bars et al., 2001). Given the complex molecular changes
that occur during long-term exposure of opioids and the
stimuli differences between antinociceptive models, it is
possible that the development of nociceptive tolerance is
model-sensitive. Another potential contributor to the
tolerance profile of UFP-505 is the dose and method of
administration used. Some recent studies have suggested a
dose dependence for the induction of opioid tolerance (Pawar
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et al., 2007; Madia et al., 2009), which increases the difficulty
of efficiently comparing data from studies that use different
opioid doses and routes of administration. A simpler explana-
tion could be that the observed residual agonist activity at δ
receptors may become important in producing tolerance.
Studies with a pure δ receptor antagonist would help to settle
this point.
Nevertheless, the profile of tolerance liability in opioids
that possess a bi- or multi-functional activity profile is not
new. A characteristic example of such a ligand is bupre-
norphine, a well-known and fully characterized complex
opioid that has been studied for more than 40 years (Lutfy
and Cowan, 2004). Although buprenorphine is a μ receptor
partial agonist, and an antagonist at δ and κ receptors (Huang
et al., 2001), its tolerance profile is somewhat similar to
morphine (Paronis and Bergman, 2011). Nevertheless, the
pharmacokinetic profile and a lack of a ceiling effect in the
clinical setting are seen as an advantage (Louis, 2006; Khanna
and Pillarisetti, 2015).
The main aim of the study was to fully characterize a
promising bifunctional ligand (based on earlier data) and to
provide insights on the potential relationship between
in vitro and in vivo activity. Full characterization of a bifunc-
tional opioid with multiple in vitro/ex vivo/in vivo assays is
important but not often performed. Our data present a
continuum from basic pharmacology to antinociceptive
actions in vivo. Specifically, this study of UFP-505 (in vitro
and in vivo) offers invaluable information on the
pharmacological properties that bifunctional opioids may
present. Unfortunately, the lack of antinociceptive efficacy
of UFP-505 via an additional subcutaneous route (see
Supporting Information Figure S1) may preclude further
development. Nevertheless, the insights gained from study-
ing UFP-505 are of value in the search for newer opioid-like
compounds with increased antinociceptive efficacy and
reduced liability for tolerance.
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